NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 11.21 against a street estimate of 8.87 — a beat of 26.4%.
with an average price target of ₹1,358.95.
| Holder | Stake |
|---|---|
| Life Insurance Corporation of India P & GS Fund | 12.14% |
| Isif Equity Ex-top 100 Long-short Fund | 5.76% |
| NPS Trust-a/c SBI Pension Fund Scheme Tax Saver-tier 2 | 2.93% |
| Nippon Life India Trustee Ltd-a/c-nippon India Nifty 50 Value 20 Index Fund | 1.58% |
| Parag Parikh Flexi Cap Fund | 1.46% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 DR. REDDY'S LABORATORIES Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Total Revenues: ₹8,071 Cr (6% YoY growth, 7% QoQ growth) • EBITDA: ₹1,009 Cr at | 2026-07-22 |
| Quarterly results · Q1 FY27 DR. REDDY'S LABORATORIES LIMITED – Q1 FY27 SUMMARY For Retail Investors | July 22, 2026 --- HEADLINE NUMBERS • Consolidated Revenues: ₹80,705 milli | 2026-07-22 |
| Q1 FY27 earnings call HEADLINE NUMBERS • No company financial, operating, or guidance information is available in the provided document. OTHER NOTABLE POINTS • The docum | 2026-07-15 |
| Annual report FY2026 DR. REDDY'S LABORATORIES LIMITED – FY2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue: ₹335,933 million ($3.6 billion USD) in FY2026, up | 2026-06-30 |
| Q4 FY26 earnings call | 2026-05-18 |
| Investor presentation · Q4 FY26 DR. REDDY'S LABORATORIES LTD – Q4 & FY26 RESULTS SUMMARY HEADLINE NUMBERS • Q4FY26 Reported Revenue: ₹7,516 Cr (12% YoY growth, 14% QoQ growth) • Q4 | 2026-05-12 |
| Quarterly results · Q4 FY26 DR. REDDY'S LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Full Year FY26 Revenue: ₹335,933 million, up 3.2% YoY (Q4 revenue ₹75,162 mi | 2026-05-12 |
| Q3 FY26 earnings call DR. REDDY'S LABORATORIES LIMITED – Q3FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenues: ₹8,727 crores (US$971 million), up 4.4% YoY, do | 2026-01-27 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹8 / share ex-date Jul 10, 2026 | 2026-07-10 |
| Announcement | Date |
|---|---|
| Acquires Progynova and Cyclo-Progynova brands for HRT segment Dr. Reddy's Laboratories has acquired the brands Progynova® and Cyclo-Progynova® in India, marking its entry into the Hormone Replacement Therapy (HRT) segment. These are established pharmac | 2026-02-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Reddy's Laboratories Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.